{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=23",
    "query": {
      "condition": "High-Risk",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T04:11:18.388Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05889156",
      "title": "Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Triglycerides"
      ],
      "interventions": [
        {
          "name": "NST-1024",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NorthSea Therapeutics B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-06-30",
      "completion_date": "2025-04-11",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05889156"
    },
    {
      "nct_id": "NCT05327023",
      "title": "Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "donor lymphocyte infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 430,
      "start_date": "2022-05-23",
      "completion_date": "2029-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05327023"
    },
    {
      "nct_id": "NCT03365661",
      "title": "QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-Risk Acute Myeloid Leukemia",
        "Treatment-Related Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-10-30",
      "completion_date": "2023-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03365661"
    },
    {
      "nct_id": "NCT00392886",
      "title": "Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "Up to 10 Years"
      },
      "enrollment_count": 120,
      "start_date": "2004-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00392886"
    },
    {
      "nct_id": "NCT00203424",
      "title": "Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib + Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Translational Oncology Research International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2006-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-25",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 16,
      "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 12 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203424"
    },
    {
      "nct_id": "NCT04790370",
      "title": "Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Anticoagulation with heparin",
          "type": "DRUG"
        },
        {
          "name": "EkoSonicTM Endovascular System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 544,
      "start_date": "2021-08-02",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04790370"
    },
    {
      "nct_id": "NCT06186167",
      "title": "Amyloidosis Incidence in High-Risk Cardiac Device Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloid",
        "Cardiac Amyloidosis",
        "Amyloidosis Cardiac",
        "Systemic Amyloidosis",
        "AL Amyloidosis",
        "Infiltrative Cardiomyopathy, Amyloid",
        "ATTR Amyloidosis Wild Type"
      ],
      "interventions": [
        {
          "name": "Chest Wall Fat Tissue Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Midwest Heart & Vascular Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-01-29",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06186167"
    },
    {
      "nct_id": "NCT05289167",
      "title": "Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "14 Years to 100 Years"
      },
      "enrollment_count": 74,
      "start_date": "2022-03-13",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 1,
      "location_summary": "New Hyde Park, New York",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289167"
    },
    {
      "nct_id": "NCT00126607",
      "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Salivary Gland Mucoepidermoid Carcinoma",
        "Recurrent Salivary Gland Cancer",
        "Salivary Gland Acinic Cell Tumor",
        "Salivary Gland Adenocarcinoma",
        "Salivary Gland Poorly Differentiated Carcinoma",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVC Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126607"
    },
    {
      "nct_id": "NCT00563901",
      "title": "Analyzing How Genetics May Affect Response to High Blood Pressure Medications",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypertension",
        "Coronary Disease",
        "Cerebrovascular Accident"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 37939,
      "start_date": "2000-09",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-11-06T04:11:18.388Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Houston, Texas",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00563901"
    }
  ]
}